Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. (symbol: VVOS) is a leading medical technology company dedicated to providing innovative solutions for patients suffering from sleep disordered breathing (SDB), particularly mild-to-moderate obstructive sleep apnea (OSA). The company specializes in the development and commercialization of proprietary treatment protocols and customized oral appliances, known collectively as the Vivos System. This non-surgical, non-invasive, and non-pharmaceutical system is designed to address craniofacial and anatomical anomalies associated with OSA, offering a cost-effective alternative to traditional treatments.
The Vivos System combines the expertise of specially trained dentists and medical professionals to deliver comprehensive care. Through its Vivos Integrated Healthcare Network, the company enables healthcare providers, including general dentists, medical doctors, myofunctional therapists, and chiropractors, to offer targeted therapies for SDB. Additionally, Vivos licenses its intellectual property to third-party manufacturers to fabricate these advanced appliance devices, expanding its reach and impact.
Recent developments at Vivos Therapeutics highlight the company's commitment to improving patient outcomes. The favorable update to United Healthcare's medical policy now endorses oral appliance therapies, potentially increasing the adoption of Vivos devices. Furthermore, the recall of numerous CPAP devices by ResMed and Philips Respironics presents a significant revenue opportunity for Vivos.
The company has also achieved a significant milestone with the introduction of the first Medicare-accepted oral appliance treatment for all severities of obstructive sleep apnea in adults. This breakthrough enhances the accessibility of effective OSA treatment to a broader patient population.
Vivos Therapeutics continues to position itself as a pioneer in the medical technology space, driven by its mission to improve the quality of life for patients with sleep-disordered breathing. Stay informed about Vivos Therapeutics' latest news and developments to understand the dynamic landscape of this innovative company.
Vivos Therapeutics (VVOS) reported a revenue of $3.5 million for Q1 2022, a slight increase from $3.4 million in Q1 2021. Appliance revenue rose 19%, with 2,965 units sold. Gross profit decreased to $2.4 million, resulting in a gross margin of 68%. The company treated approximately 27,000 patients and trained over 1,500 dentists, marking significant growth. Vivos plans to open its third Pneusomnia Sleep Center in May 2022, aiming for more in the year. CEO R. Kirk Huntsman noted improvements starting in March, citing a 28% increase in appliance sales.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its financial results for Q1 2022 on May 16, 2022, after market close. A conference call will follow at 5:00 pm ET, where management will discuss results and strategic milestones. The company focuses on innovative solutions for dentofacial abnormalities and mild to moderate obstructive sleep apnea (OSA). The Vivos Method has effectively treated approximately 25,000 patients globally by trained dentists. A replay of the call will be available until May 30, 2022, along with a webcast accessible on Vivos' website.
Vivos Therapeutics, a medical technology company, announced the opening of its third Pneusomnia Sleep Center in Toluca Lake, California, in May 2022. This center aims to provide a comprehensive treatment approach for obstructive sleep apnea (OSA)
Vivos Therapeutics (NASDAQ: VVOS) reported a 33% increase in fourth quarter revenue, totaling $4.4 million, and a 29% increase for the full year, reaching $16.9 million. The growth was driven by increased appliance sales and new revenue sources. The total number of oral appliance arches sold rose to 2,707 in Q4 and 11,355 for the full year. Gross profit was $3.1 million in Q4, with a gross margin of 71%. Vivos also secured its mmRNA device's acceptance by Medicare and registered products with Health Canada. Management will hold a conference call today at 5:00 pm ET.
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company, will release its fourth quarter and full year 2021 financial results today, March 31, 2022, following market close. The company will host a conference call at 5:00 PM ET to discuss the results and outline its growth strategy. Vivos specializes in innovative treatments for dentofacial abnormalities and obstructive sleep apnea, with its method having been effective for approximately 25,000 patients globally.
Vivos Therapeutics (NASDAQ: VVOS) has been recognized by Fast Company as the 9th most innovative medical device company in 2022. The company specializes in non-surgical and non-invasive treatments for dentofacial abnormalities and obstructive sleep apnea (OSA). Their proprietary technique, the Vivos Method, offers a 12-24 month treatment option that significantly improves airway conditions. Currently, over 25,000 patients have been treated using this method, addressing a market where over 1 billion people suffer from sleep apnea, many of whom remain undiagnosed.
Vivos Therapeutics has announced a rebranding of its proprietary treatment system to The Vivos Method, aimed at enhancing clarity and approachability for dentists and patients. This method combines customized oral appliances with multidisciplinary protocols to treat obstructive sleep apnea (OSA) in 12 to 24 months, offering a non-invasive alternative to traditional CPAP machines and surgeries. Vivos reports success with over 25,000 patients treated globally by more than 1,450 dentists. The updated website provides extensive information, including patient testimonials and partnership opportunities.
Vivos Therapeutics, a medical technology company focused on innovative treatment for dentofacial abnormalities and obstructive sleep apnea, announced CEO Kirk Huntsman's participation in upcoming conferences. Huntsman will present at the Q1 Virtual Investor Summit on March 8, 2022, at 4:15 PM ET and will engage in a fireside chat at the 34th Annual ROTH Conference on March 15, 2022, at 8:30 AM PT. Recordings of the presentations will be available on Vivos' website. The company aims to provide non-surgical, cost-effective solutions for sleep apnea, having treated about 25,000 patients worldwide.
Vivos Therapeutics (NASDAQ: VVOS) will present new clinical data at the World Sleep Congress in Rome from March 11-16, 2022. Dr. Seth Heckman, MD will lead the presentation on March 15, focusing on patient outcomes utilizing the Vivos Method for treating obstructive sleep apnea (OSA). The Vivos Method offers a non-surgical, effective solution, with 97% of patients achieving clinical objectives. The Medical Advisory Board, formed in October 2021, aims to enhance evidence-based practices in sleep medicine.
Vivos Therapeutics has filed a new U.S. patent application for enhanced clinical methods in treating obstructive sleep apnea (OSA) using its proprietary Vivos Method. Early data show a significant 58% improvement in Apnea Hypopnea Index (AHI) score reductions among patients treated with the revised protocols. This initiative is part of Vivos' Continuous Clinical Improvement Program aimed at refining treatment and optimizing patient outcomes. Currently, around 54 million Americans suffer from sleep apnea, highlighting the necessity for effective, non-invasive treatment alternatives.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
What does Vivos Therapeutics, Inc. specialize in?
What is the Vivos System?
Who can benefit from Vivos Therapeutics' solutions?
How does Vivos Therapeutics collaborate with healthcare providers?
What are some recent achievements of Vivos Therapeutics?
What opportunities have arisen from the recall of CPAP devices?
How does Vivos Therapeutics manufacture its oral appliances?
What makes the Vivos System unique?
Who are the target customers for Vivos Therapeutics?
What is the mission of Vivos Therapeutics?
